High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2817-2821

  Laszlo, George S ^a   Ries, Rhonda E ^a   Gudgeon, Chelsea J ^a   Harrington, Kimberly H ^a   Alonzo, Todd A ^b,c   Gerbing, Robert B ^c   Raimondi, Susana C ^c,d   Hirsch, Betsy A ^c,e   Gamis, Alan S ^c,f   Meshinchi, Soheil ^a,c,g   Walter, Roland B ^a,g,h  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f CHILDREN S MERCY HOSPITAL   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Childhood cancer; Cytokine; Prognostic factor; SOCS2

Indexed keywords

HEMOGLOBIN; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 2; SOCS2 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CONCENTRATION (PARAMETERS); CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTICENTER STUDY; NEWBORN; PILOT STUDY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM, RESIDUAL; PILOT PROJECTS; PROGNOSIS; RECURRENCE; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 84919416162     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.893305     Document Type: Article

References (23)

1. Russell NH. Autocrine growth factorsand leukaemic haemopoiesis. Blood Rev 1992; 6: 149-156.
2. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 2007;26:6738-6749.
3. Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010;116:4251-4261.
4. Fujimoto M, Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003;24:659-666.
5. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454-465.
6. Schultheis B, Carapeti-Marootian M, Hochhaus A, et al. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 2002;99:1766-1775.
7. Haffner MC, Petridou B, Peyrat JP, et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007; 7: 136.
8. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer 2012;118:761-769.
9. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654-3661.
10. Aronica MG, Brizzi MF, Dentelli P, et al. p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. Oncogene 1996;13:1017-1026.
11. Chakraborty A, White SM, Schaefer TS, et al. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood 1996;88:2442-2449.
12. Biethahn S, Alves F, Wilde S, et al. Expression of granulocyte colony-stimulating factor-and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999; 27: 885-894.
13. Han L, Wierenga AT, Rozenveld-Geugien M, et al. Single-cell STAT5 signal transduction prof ling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One 2009;4:e7989.
14. Marvin J, Swaminathan S, Kraker G, et al. Normal bone marrow signal-transduction prof les: a requisite for enhanced detection of signaling dysregulations in AML. Blood 2011; 117: e120-e130.
15. Redell MS, Ruiz MJ, Alonzo TA, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011;117:5701-5709.
16. Redell MS, Ruiz MJ, Gerbing RB, et al. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a signif cant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood 2013;121:1083-1093.
17. Piessevaux J, Lavens D, Montoye T, et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 2006;281:32953-32966.
18. Tannahill GM, Elliott J, Barry AC, et al. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005;25:9115-9126.
19. Metcalf D, Greenhalgh CJ, Viney E, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000; 405: 1069-1073.
20. Favre H, Benhamou A, Finidori J, et al. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 1999;453:63-66.
21. Greenhalgh CJ, Metcalf D, Taus AL, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002; 277: 40181-40184.
22. Kazi JU, Ronnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol 2013;7:693-703.
23. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specifc Flt3 mutations. Blood 2003;101:3164-3173.